Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2011 Apr 12;19(4):435-7. doi: 10.1016/j.ccr.2011.03.019.

Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia.

Author information

  • 1Division of Tumour Biology, The Institute of Cancer Research, London, UK.


ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL(T315I) mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that "switch-control" inhibitors block BCR-ABL(T315I) activity by preventing ABL from switching from the inactive to active conformation.

Copyright © 2011 Elsevier Inc. All rights reserved.

Comment on

Free full text

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk